Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy

COVID Clinical Trial

— (ESCAPE)  

Official title:

A Prospective, Randomized, Double-Masked, Placebo-Controlled Trial of High-Titer COVID-19 Convalescent Plasma (HT-CCP) for the Treatment of Hospitalized Patients With COVID-19 of Moderate Severity

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04361253
• Other study ID #: 2020P001215
• Status: Terminated
• Phase: Phase 3
• Start date: April 30, 2020
• Est. completion date: June 30, 2021

Study information

• Verified date: August 2021
• Source: Brigham and Women's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, investigators will determine whether the early addition of HT-CCP to standard treatment improves the clinical outcome (as assessed by the Modified WHO Ordinal Scale) of patients with COVID-19 who are hospitalized but not yet in moderate or severe ARDS.

Description:

Investigators are doing this research to learn more about high-titer COVID-19 convalescent plasma (HT-CCP) transfusion as a possible treatment for people who have COVID-19, the coronavirus infection. "HT-CCP" is plasma that contains a high amount of antibodies that were made to fight off COVID-19 because it is donated by another person who has also been infected with coronavirus but has recovered, so their immune system has had enough time to make these antibodies. This study is being done to determine whether HT-CCP will help people with COVID-19 recover from their infection more quickly and lower their risk of having to go on a ventilator or reduce the time they need to stay on a ventilator. It is not yet known whether HT-CCP helps people with COVID-19, which is why the study needs to be randomized, meaning some subjects will be randomly selected to receive HT-CCP while others will be randomly selected to receive FFP.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 45
• Est. completion date: June 30, 2021
• Est. primary completion date: April 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Months and older

Eligibility

Inclusion Criteria:

1. Age >1 year.

2. Active COVID-19 infection confirmed by positive SARS-CoV-2 PCR.

3. Meets institutional criteria for admission to hospital for COVID-19.

4. Admitted to ICU or non-ICU floor within 5 days of enrollment.

5. PaO2/FiO2 >200 mmHg if intubated.

6. Patient or LAR able to provide informed consent.

Exclusion Criteria:

1. Previous treatment with convalescent plasma for COVID-19.

2. Current use of investigational antiviral therapy targeting SARS-CoV-2.

3. History of anaphylactic transfusion reaction.

4. Clinical diagnosis of acute decompensated heart failure.

5. Objection to blood transfusion.

Related Conditions & MeSH terms

• Communicable Diseases
• COVID
• Infection
• Infectious Disease

Intervention

Biological:
• High-Titer COVID-19 Convalescent Plasma (HT-CCP)
250mL HT-CCP x2 doses given sequentially.
• Standard Plasma (FFP)
250mL FFP or FP24 x2 doses given sequentially.

Locations

Country	Name	City	State
United States	Brigham and Women's Hospital	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Brigham and Women's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Modified WHO Ordinal Scale (MOS) score	The primary outcome will be the MOS numerical score (score 0-9) where a score of 0 attributes to 'no clinical evidence of infection' and a score of 9 attributes to 'death'. The eligibility requirements for this trial select individuals at level 3 or higher on the modified scale, but the day 14 outcome can be any one of 10 levels.	Day 14